Integra LifeSciences (NASDAQ:IART) Shares Gap Down Following Analyst Downgrade

Integra LifeSciences Holdings Corporation (NASDAQ:IART) gapped down before the market opened on Wednesday after Truist Financial lowered their price target on the stock from $13.00 to $12.00. The stock had previously closed at $11.06, but opened at $10.60. Truist Financial currently has a hold rating on the stock. Integra LifeSciences shares last traded at $11.01, with a volume of 97,263 shares trading hands.

Several other brokerages have also recently issued reports on IART. Wells Fargo & Company raised shares of Integra LifeSciences to a “hold” rating in a research note on Wednesday, March 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. Citigroup lowered their price objective on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating for the company in a research note on Wednesday, March 11th. Wall Street Zen cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Argus reissued a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $14.20.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allianz Asset Management GmbH lifted its holdings in Integra LifeSciences by 88.7% in the 3rd quarter. Allianz Asset Management GmbH now owns 433,738 shares of the life sciences company’s stock worth $6,215,000 after buying an additional 203,834 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in Integra LifeSciences in the 3rd quarter worth $2,407,000. SG Americas Securities LLC acquired a new position in Integra LifeSciences in the 4th quarter worth $4,722,000. Assenagon Asset Management S.A. lifted its holdings in Integra LifeSciences by 15.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company’s stock worth $6,537,000 after buying an additional 71,950 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Integra LifeSciences in the 2nd quarter worth $765,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54. The stock has a market cap of $859.68 million, a price-to-earnings ratio of -1.64 and a beta of 1.06. The business’s fifty day simple moving average is $10.23 and its 200 day simple moving average is $12.02.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm had revenue of $434.93 million for the quarter, compared to analyst estimates of $429.62 million. During the same quarter in the previous year, the business posted $0.97 EPS. The firm’s revenue was down 1.7% compared to the same quarter last year. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.